[go: up one dir, main page]

MX2018013864A - Métodos para la expansión selectiva de poblaciones de células t gama y composicicones de estas. - Google Patents

Métodos para la expansión selectiva de poblaciones de células t gama y composicicones de estas.

Info

Publication number
MX2018013864A
MX2018013864A MX2018013864A MX2018013864A MX2018013864A MX 2018013864 A MX2018013864 A MX 2018013864A MX 2018013864 A MX2018013864 A MX 2018013864A MX 2018013864 A MX2018013864 A MX 2018013864A MX 2018013864 A MX2018013864 A MX 2018013864A
Authority
MX
Mexico
Prior art keywords
methods
compositions
cell populations
selective expansion
alpha
Prior art date
Application number
MX2018013864A
Other languages
English (en)
Inventor
Li Yan
Foord Orit
Jakobovits Aya
An- Deh Lin Andy
Chetan Desai Radhika
Kadyl Satpayev Daulet
Theresa SANTAGUIDA Marianne
Frank Jing Yifeng
Original Assignee
Adicet Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adicet Bio Inc filed Critical Adicet Bio Inc
Publication of MX2018013864A publication Critical patent/MX2018013864A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a métodos para la expansión selectiva de la o las poblaciones de células T ?d, composiciones y mezclas de estos y métodos para utilizar los mismos como una terapia. Poblaciones de células T ?d enriquecidas, no modificadas y modificadas de la descripción son útiles en el tratamiento de diversos cánceres, enfermedades infecciosas y trastornos autoinmunes.
MX2018013864A 2016-05-12 2017-05-12 Métodos para la expansión selectiva de poblaciones de células t gama y composicicones de estas. MX2018013864A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662335572P 2016-05-12 2016-05-12
PCT/US2017/032530 WO2017197347A1 (en) 2016-05-12 2017-05-12 METHODS FOR SELECTIVE EXPANSION OF γδ T-CELL POPULATIONS AND COMPOSITIONS THEREOF

Publications (1)

Publication Number Publication Date
MX2018013864A true MX2018013864A (es) 2019-06-10

Family

ID=60267413

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018013864A MX2018013864A (es) 2016-05-12 2017-05-12 Métodos para la expansión selectiva de poblaciones de células t gama y composicicones de estas.
MX2023006546A MX2023006546A (es) 2016-05-12 2018-11-12 Metodos para la expansion selectiva de poblaciones de celulas t gama y composiciones de estas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023006546A MX2023006546A (es) 2016-05-12 2018-11-12 Metodos para la expansion selectiva de poblaciones de celulas t gama y composiciones de estas.

Country Status (11)

Country Link
US (2) US11299708B2 (es)
EP (1) EP3454870A4 (es)
JP (3) JP7210286B2 (es)
KR (1) KR102519861B1 (es)
CN (2) CN110072533B (es)
AU (2) AU2017261804A1 (es)
CA (1) CA3023993A1 (es)
IL (2) IL262919B2 (es)
MX (2) MX2018013864A (es)
WO (1) WO2017197347A1 (es)
ZA (1) ZA201808140B (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3333186B9 (en) 2012-03-28 2023-10-04 Gadeta B.V. Combinatorial gamma 9 delta 2 t cell receptor chain exchange
CN110072533B (zh) 2016-05-12 2024-04-02 阿迪塞特治疗公司 选择性扩增γδT细胞群的方法及其组合物
KR102489954B1 (ko) 2016-06-10 2023-01-19 가데타 비.브이. 인간 백혈구 항원 제한된 감마 델타 t 세포 수용체 및 이의 사용 방법
EP3494132A4 (en) 2016-08-03 2020-03-18 Washington University Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
MY200528A (en) * 2017-02-08 2023-12-30 Agency Science Tech & Res Gamma delta t cells and a method of augmenting the tumoricidal activity of the same
CA3063807A1 (en) * 2017-05-18 2018-11-22 Umc Utrecht Holding B.V. Compositions and methods for cell targeting therapies
EP3692058A1 (en) 2017-10-06 2020-08-12 Oslo Universitetssykehus HF Chimeric antigen receptors
EP3710472A1 (en) 2017-11-15 2020-09-23 Adicet Bio Inc. Methods for selective expansion of delta 3 gamma delta t-cell populations and compositions thereof
EP3743081A4 (en) * 2018-01-23 2021-12-01 New York University SPECIFIC ANTIBODIES OF THE DELTA 1 CHAIN OF THE T-LYMPHOCYTE RECEPTOR
WO2019160829A1 (en) * 2018-02-13 2019-08-22 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
WO2019183610A1 (en) * 2018-03-23 2019-09-26 La Jolla Institute For Allergy And Immunology Tissue resident memory cell profiles, and uses thereof
GB201804701D0 (en) 2018-03-23 2018-05-09 Gammadelta Therapeutics Ltd Lymphocytes expressing heterologous targeting constructs
EP3796923A4 (en) * 2018-05-18 2022-03-09 Children's National Medical Center Improved targeted t-cell therapy
US20210283180A1 (en) * 2018-07-06 2021-09-16 The Arizona Board Of Regents On Behalf Of The University Of Arizona Car t cell therapy to target t cell specific cancers
CN112955466A (zh) * 2018-07-20 2021-06-11 杜克大学 用于癌症治疗的抗lypd3 car t细胞疗法
JP7565271B2 (ja) * 2018-07-26 2024-10-10 オスペダーレ ペディアトリコ バンビーノ ジェズ ガンマ－デルタｔ細胞およびナチュラルキラー細胞の治療的調製物ならびに製造および使用する方法
US12077586B2 (en) 2018-09-19 2024-09-03 LAVA Therapeutics N.V. Bispecific antibodies for use in the treatment of hematological malignancies
CN109234236A (zh) * 2018-09-29 2019-01-18 吉林大学第医院 一种嵌合抗原受体γδT细胞的制备方法
BR112021006182A2 (pt) * 2018-10-01 2021-06-29 Adicet Bio, Inc. composições e métodos relativos a células t¿d,d engenheiradas e não engenheiradas para tratamento de tumores hematológicos
AU2019354395A1 (en) * 2018-10-01 2021-05-06 Adicet Therapeutics, Inc. Compositions and methods regarding engineered and non-engineered γδ -T cells for treatment of solid tumors
GB2569692A (en) * 2018-10-30 2019-06-26 Tc Biopharm Ltd T cell antigen receptor chimera
CN112969469A (zh) * 2018-11-05 2021-06-15 艾欧凡斯生物治疗公司 抗pd-1抗体难治性nsclc患者的治疗
BR112021010804A2 (pt) * 2018-12-03 2021-11-16 Adicet Bio Inc Métodos para expansão seletiva in vivo de populações de células t gama delta e composições das mesmas
JP7549584B2 (ja) 2019-01-23 2024-09-11 ニューヨーク・ユニバーシティ Ｔ細胞受容体のデルタ１鎖に特異的な抗体
CA3132028A1 (en) * 2019-03-30 2020-10-08 Biontech Us Inc. Compositions and methods for preparing t cell compositions and uses thereof
MX2022001977A (es) * 2019-08-16 2022-03-11 Gammadelta Therapeutics Ltd Poblaciones de celulas t gamma delta t ex vivo.
MX2022002075A (es) * 2019-08-16 2022-03-17 Gammadelta Therapeutics Ltd Usos terapeuticos de anticuerpos anti-variable delta 1 de tcr.
DK4051710T3 (da) 2019-10-31 2025-12-15 Incyte Corp Antitumor-kombinationsterapi bestående af anti-cd19-antistof og gamma-delta-t-celler
CN115397976A (zh) * 2019-12-03 2022-11-25 阿迪塞特生物股份有限公司 用多价药剂及其组合物扩增γδT细胞群的方法
WO2021142260A1 (en) * 2020-01-10 2021-07-15 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for modulation of acvr1
GB202002581D0 (en) * 2020-02-24 2020-04-08 Gammadelta Therapeutics Ltd Novel antibodies
KR20220154190A (ko) * 2020-03-13 2022-11-21 얀센 바이오테크 인코포레이티드 델타 사슬 매개 면역을 조절하기 위한 물질 및 방법
CA3173176A1 (en) * 2020-05-07 2021-11-11 Huiwen WU Anti-tumor associated antigen antibodies and uses thereof
GB202006989D0 (en) * 2020-05-12 2020-06-24 Gammadelta Therapeutics Ltd Methods for isolating gamma delta t cells
CN111748519A (zh) * 2020-07-06 2020-10-09 深圳市人民医院 成纤维细胞的原代培养方法
AU2021324767A1 (en) * 2020-08-12 2023-04-13 University Of Central Florida Research Foundation, Inc. Methods and compositions for stimulating gamma delta T cells
KR20230083267A (ko) 2020-08-14 2023-06-09 감마델타 테라퓨틱스 엘티디 다중특이적 항-tcr 델타 가변 1 항체
GB202013962D0 (en) * 2020-09-04 2020-10-21 Gammadelta Therapeutics Ltd Immunotherapy composition
MX2023009544A (es) 2021-02-17 2023-11-28 Gammadelta Therapeutics Ltd Anticuerpos anti-variable delta 1 de tcr multiespecíficos.
BR112023016580A2 (pt) * 2021-02-17 2023-11-07 Gammadelta Therapeutics Ltd Anticorpos anti-tcr delta variáveis 1
WO2022258606A1 (en) * 2021-06-07 2022-12-15 Gadeta B.V. Delta T-cell or Gamma T-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response
EP4419118A4 (en) * 2021-10-20 2025-04-30 University of Pittsburgh - Of the Commonwealth System of Higher Education Methods and materials for expanding tumor infiltrating gamma-delta t cells
US11999968B2 (en) * 2021-10-22 2024-06-04 Fullhope Biomedical Co., Ltd Modified T cells, pharmaceutical composition, manufacturing method thereof, and method of using the same
CA3238458A1 (en) * 2021-11-18 2023-05-25 Regents Of The University Of Minnesota Large-scale expansion of engineered human gamma delta t cells
EP4444324A4 (en) * 2021-12-09 2025-10-08 Univ Melbourne MODIFIED T CELL RECEPTORS AND THEIR USES
JP2025506506A (ja) 2022-02-16 2025-03-11 プリオセラ エスエーエス Ｓ１ｐ受容体モジュレーターと組み合わせたｃａｒ細胞を用いた処置方法
CA3208653A1 (en) 2022-02-17 2022-08-25 Mihriban Tuna Multispecific anti-tcr delta variable 1 antibodies
WO2023250336A1 (en) * 2022-06-21 2023-12-28 Kiromic BioPharma, Inc. Methods for generating gamma delta t-cells and related compositions
EP4544302A1 (en) * 2022-06-23 2025-04-30 LAVA Therapeutics N.V. Assay for t cell dependent multispecific compounds
KR20250144510A (ko) * 2022-11-02 2025-10-10 티젠 파마 에스에이 림프구 확장
WO2024130090A1 (en) * 2022-12-15 2024-06-20 The Regents Of The University Of California Enhanced gamma delta t cells for immunotherapy
WO2024238812A2 (en) * 2023-05-16 2024-11-21 The Brigham And Women’S Hospital, Inc. Metabolically enhanced vd1 t cells and uses thereof
WO2025022361A1 (en) * 2023-07-26 2025-01-30 Janssen Biotech, Inc. Materials and methods for cell growth
WO2025045018A1 (en) * 2023-08-31 2025-03-06 Nanjing Legend Biotech Co., Ltd. Anti-gamma delta tcr antibodies and uses thereof
TW202537974A (zh) * 2023-11-15 2025-10-01 大陸商上海盛迪醫藥有限公司 Ｔｒｇｖ９結合蛋白及其醫藥用途
WO2026013158A1 (en) 2024-07-10 2026-01-15 Cytospire Therapeutics Limited Antibodies binding to constant domains of gamma delta t-cell receptors
WO2026013159A1 (en) 2024-07-10 2026-01-15 Cytospire Therapeutics Limited Antibodies binding to constant domains of gamma delta t-cell receptors

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185250A (en) 1986-07-03 1993-02-09 T Cell Sciences, Inc. Human γ, δT cell antigen receptor polypeptides and nucleic acids
US5260223A (en) 1986-07-03 1993-11-09 President & Fellows Of Harvard College Methods for detection of human gamma, γ T cell receptor
EP0633943A4 (en) 1992-04-03 1997-05-02 Alexander T Young GENTHERAPY USING TARGETED VIRAL VECTORS.
CA2110946A1 (en) 1992-12-09 1994-06-10 Elazar Rabbani Induction of immunocompatibility by nucleic acid
AU783250B2 (en) 1999-06-17 2005-10-06 Dartmouth College Autologous adoptive immunotherapy with primed antigen-specific T cells or B cells
EP1229790A4 (en) 1999-09-30 2004-06-16 Nat Jewish Med & Res Center MODULATION OF -G (G) -G (D) T CELLS FOR REGULATING THE RESPIRATORY HYPERSENSITIVITY
US6737398B1 (en) 1999-09-30 2004-05-18 National Jewish Medical And Research Center Modulation of γδ T cells to regulate airway hyperresponsiveness
BRPI0307383B1 (pt) 2002-01-23 2019-12-31 The Univ Of Utah Research Foundation método de recombinação genética direcionada em célula de planta hospedeira
CN1306027C (zh) 2002-12-12 2007-03-21 中国医学科学院基础医学研究所 一种体外扩增γδT淋巴细胞的方法
WO2004092741A2 (en) 2003-04-14 2004-10-28 Montana State University Mapping discontinuous antibody or aptamer epitopes for protein structure determination and other applications
US7985739B2 (en) 2003-06-04 2011-07-26 The Board Of Trustees Of The Leland Stanford Junior University Enhanced sleeping beauty transposon system and methods for using the same
SG10201606980VA (en) 2004-06-03 2016-10-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
US7340913B2 (en) 2004-08-05 2008-03-11 Manitowoc Foodservice Companies, Inc. Ice machine and ice-making assembly including a water distributor
US20080026986A1 (en) 2006-06-05 2008-01-31 Rong-Fu Wang Reversal of the suppressive function of specific t cells via toll-like receptor 8 signaling
IL226291A (en) 2006-09-08 2016-05-31 Abbvie Bahamas Ltd A binding protein that links interleukin-13, its pharmaceutical composition and its use in the preparation of a drug.
WO2010027797A1 (en) 2008-08-26 2010-03-11 Macrogenics Inc. T-cell receptor antibodies and methods of use thereof
UA118328C2 (uk) 2010-01-22 2019-01-10 Дау Агросайєнсіз Ллс Спосіб інтегрування екзогенних послідовностей у геном рослинної клітини
BR112012018115B1 (pt) 2010-01-23 2021-06-22 Genefluidics, Inc. Sistema configurado para transportar um líquido armazenado em um ou mais reservatórios dentro de uma ou mais câmaras funcionais, e, método de operação do sistema
US8324914B2 (en) * 2010-02-08 2012-12-04 Genia Technologies, Inc. Systems and methods for characterizing a molecule
CA2805442C (en) 2010-07-21 2020-05-12 Sangamo Biosciences, Inc. Methods and compositions for modification of an hla locus
CN103619882B (zh) 2011-04-01 2016-10-19 纪念斯隆-凯特琳癌症中心 对hla-a2呈递的wt1肽特异的t细胞受体样抗体
ES2643387T3 (es) * 2011-05-19 2017-11-22 Instituto De Medicina Molecular Estirpe celular de linfocitos que comprende células gama-delta, composición y método de producción de la misma
US10391126B2 (en) 2011-11-18 2019-08-27 Board Of Regents, The University Of Texas System CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
US9624298B2 (en) 2011-11-28 2017-04-18 Merck Patent Gmbh Anti-PD-L1 antibodies and uses thereof
CN109182266A (zh) * 2011-12-12 2019-01-11 细胞药物有限公司 扩大t细胞的方法
EP2684600A1 (en) 2012-07-10 2014-01-15 Laboratoires Meiners Sarl Core-shell capsules and methods for encapsulation of reactive ingredients by diffusional exchange through spherical capsule membranes
WO2014072446A1 (en) * 2012-11-08 2014-05-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for inducing il-2-free proliferation of gamma delta t cells
CN102994448A (zh) 2012-12-13 2013-03-27 上海柯莱逊生物技术有限公司 一种体外扩增γδT细胞的方法
JP6480874B2 (ja) 2013-03-01 2019-03-13 リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミネソタＲｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉｎｎｅｓｏｔａ Ｔａｌｅｎに基づく遺伝子修正
JP2016539929A (ja) * 2013-10-25 2016-12-22 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 免疫療法のためのポリクローナルγδＴ細胞
KR102359264B1 (ko) 2014-04-10 2022-02-04 라바 테라퓨틱스 비.브이. 인간 Vγ9Vδ2 T 세포에 결합하는 면역글로불린
CN107249605A (zh) * 2014-11-17 2017-10-13 阿迪塞特生物股份有限公司 工程化的γδT细胞
AU2016274633B2 (en) * 2015-06-09 2022-04-21 Gammadelta Therapeutics Ltd Methods for the production of TCR gamma delta+ T cells
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
CN110072533B (zh) 2016-05-12 2024-04-02 阿迪塞特治疗公司 选择性扩增γδT细胞群的方法及其组合物

Also Published As

Publication number Publication date
EP3454870A4 (en) 2020-03-04
CN110072533B (zh) 2024-04-02
JP2019519210A (ja) 2019-07-11
KR20190016960A (ko) 2019-02-19
IL301527A (en) 2023-05-01
JP7791789B2 (ja) 2025-12-24
US20190119634A1 (en) 2019-04-25
AU2023278051A1 (en) 2024-02-01
CN118421557A (zh) 2024-08-02
EP3454870A1 (en) 2019-03-20
KR102519861B1 (ko) 2023-04-10
MX2023006546A (es) 2023-06-16
AU2017261804A1 (en) 2018-11-29
CA3023993A1 (en) 2017-11-16
US12364714B2 (en) 2025-07-22
IL262919A (en) 2018-12-31
US11299708B2 (en) 2022-04-12
IL301527B1 (en) 2025-11-01
JP7210286B2 (ja) 2023-01-23
WO2017197347A1 (en) 2017-11-16
JP2025170245A (ja) 2025-11-18
JP2022180371A (ja) 2022-12-06
CN110072533A (zh) 2019-07-30
IL262919B1 (en) 2023-04-01
ZA201808140B (en) 2024-03-27
US20220372439A1 (en) 2022-11-24
IL262919B2 (en) 2023-08-01

Similar Documents

Publication Publication Date Title
MX2018013864A (es) Métodos para la expansión selectiva de poblaciones de células t gama y composicicones de estas.
MX2019002904A (es) Composiciones de arn de alta pureza y métodos para su preparación.
CL2025001440A1 (es) Medios y método para preparar vectores virales y usos de los mismos
MX2019009468A (es) Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer.
CY1125436T1 (el) Αναστολεις dna-pk
AR120223A1 (es) Proteínas que unen nkg2d, cd16 y flt3
CY1123142T1 (el) Βελτιωμενες μεθοδοι για την παραγωγη θετων κυτταρικων θεραπειων
MX2017006408A (es) Linfocitos t gamma delta modificados geneticamente.
MX390014B (es) Compuestos de dinucleótidos cíclicos y métodos de uso.
CR11817A (es) Anticuerpos anti-factor d humanizados y sus usos
MX2017016024A (es) Composiciones de nicotinamida ribósido y pteroestilbeno y métodos para el tratamiento de trastornos de la piel.
MX2015001871A (es) Celulas asesinas naturales y usos de las mismas.
CY1118900T1 (el) Δικυκλικως υποκατεστημενες ουρακιλες και η χρηση αυτων
CU20170056A7 (es) Métodos para tratar infecciones por el virus filoviridae
MX2018004600A (es) Celulas aniquiladoras naturales y células ilc3 y usos de las mismas.
DOP2013000036A (es) Derivados de ciclobutano como inhibidores de jak
PE20151157A1 (es) Formas de dosificacion de ruxolitinib de liberacion sostenida
CR20110192A (es) Compuestos que expanden las celulas madres hematopoiéticas
CO2021005509A2 (es) Derivados de piridinil sulfonamida, composiciones farmacéuticas y usos de estos
UY36171A (es) Derivados heteroaromáticos bicíclicos fusionados como inhibidores de quinasa
UY35625A (es) Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos como inhibidores de quinasa
MX2017003903A (es) Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles.
MX2018006373A (es) Produccion de virus en cultivos celulares.
MX2022003039A (es) Metodo de seleccion de donantes universales para identificar donantes de celulas nk.
CO2017002312A2 (es) Compuestos bicíclicos sustituidos